Immunologic and clinical stages in HIV-1-infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advanced disease.

Clear understanding of the natural history of HIV-1 disease is critical for planning and developing appropriate therapeutic strategies for HIV-1-infected populations in the developing world. Present knowledge about Africa is based on very limited data that largely use clinical staging as the prognostic marker; this approach has not been prospectively validated. Our objectives were to compare clinical staging and CD4+ T-cell counts as prognostic tools and to describe survival and cause of death in seroprevalent HIV-1-infected Ugandan adults by means of a prospective cohort study. Consecutive HIV-1-infected adults registering with a community HIV/AIDS clinic in Entebbe, Uganda were enrolled between October 1994 to January 1995 and observed during follow-up until the end of December 1997. Baseline CD4+ T-cell count distribution showed clear and appropriate associations with clinical stage in the 201 participants. Both provided equivalent prognostic information: median survival with CD4+ T-cell count <200 cells/microl was 9 months (95% confidence interval [CI], 7-15 months) compared with 19 and 7 months (95% CI, 10-28 and 0-8 months, respectively) in clinical stages 3 and 4, respectively; survival at 3 years with CD4+ T-cell count > or =200 cells/microl was 68% and for clinical stage 1 and 2, 80% and 60%, respectively. Clinical stage 3 and 4 were 76% sensitive and 65% specific for predicting a CD4+ T-cell count <200 cells/microl, positive predictive value of 56%, negative predictive value 78%. In all, 82 participants died (41%; mortality rate 216 of 1000 person-years) and was strongly associated with low CD4+ T-cell counts. In conclusion, clinical staging is valid and comparable with staging by CD4 T-cell counts for epidemiologic measurements. Mortality with early disease in Entebbe appears equivalent to that found in the developed world but there is poor survival with advanced disease.

[1]  N. French,et al.  Pneumococcal vaccination in HIV‐1‐infected adults in Uganda: humoral response and two vaccine failures , 1998, AIDS.

[2]  J. Whitworth,et al.  Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. , 1998, International journal of epidemiology.

[3]  J. Stephenson,et al.  Disease progression and survival in HIV‐1‐infected Africans in London , 1998, AIDS.

[4]  J. Whitworth,et al.  Early manifestations (pre‐AIDS) of HIV‐1 infection in Uganda , 1998, AIDS.

[5]  R. Hayes,et al.  Profound immunosuppression across the spectrum of opportunistic disease among hospitalized HIV‐infected adults in Abidjan, Côte d'Ivoire , 1997, AIDS.

[6]  J. Whitworth,et al.  HIV-1 disease progression and AIDS-defining disorders in rural Uganda , 1997, The Lancet.

[7]  J. Chmiel,et al.  Survival from early, intermediate, and late stages of HIV infection. , 1996, JAMA.

[8]  F. Plummer,et al.  Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya , 1996, The Lancet.

[9]  R. Chaisson,et al.  Race, sex, drug use, and progression of human immunodeficiency virus disease. , 1995, The New England journal of medicine.

[10]  H. Kessler,et al.  HIV infection in women: an observational study of clinical characteristics, disease progression, and survival for a cohort of women in Chicago. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[11]  N. Nagelkerke,et al.  Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. , 1995, The Journal of infectious diseases.

[12]  E. Hudes,et al.  Classification of HIV Infection and Disease in Women from Rwanda: Evaluation of the World Health Organization HIV Staging System and Recommended Modifications , 1995, Annals of Internal Medicine.

[13]  S. Buchbinder,et al.  Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1991. , 1994, American journal of epidemiology.

[14]  S. Shiboski,et al.  Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. , 1994, JAMA.

[15]  C. Gilks.  The clinical challenge of the HIV epidemic in the developing world , 1993, The Lancet.

[16]  G. Mills,et al.  Relationship between CD4 lymphocyte count and AIDS mortality, 1986–1991 , 1993, AIDS.

[17]  J. Montaner,et al.  Application of the World Health Organization system for HIV infection in a cohort of homosexual men in developing a prognostically meaningful staging system , 1992, AIDS.

[18]  S. Hulley,et al.  Predictors of Mortality among HIV-infected Women in Kigali, Rwanda , 1992, Annals of Internal Medicine.

[19]  C. Gilks,et al.  The presentation and outcome of HIV-related disease in Nairobi. , 1992, The Quarterly journal of medicine.

[20]  H. Taelman,et al.  Cryptococcosis, another growing burden for central Africa , 1991, The Lancet.

[21]  B. Truman,et al.  Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. , 1987, The New England journal of medicine.